Diagnosing pulmonary fibrosis typically involves a combination of imaging, breathing tests, blood work, and sometimes a tissue sample. There is no single test that confirms it. Instead, doctors piece together findings from several sources, often after ruling out other conditions first. The process can take a while: the median time from first symptoms to a definitive diagnosis is about 14 months, and roughly 41% of patients report being misdiagnosed along the way, often with conditions like COPD, pneumonia, or heart failure.
What Happens at the Physical Exam
The first clue often comes from a stethoscope. When a doctor listens to the lungs of someone with pulmonary fibrosis, they typically hear a distinctive crackling sound during inhalation. These are sometimes called “velcro crackles” because they sound like tearing open a strip of velcro. They’re caused by scarred, stiff lung tissue snapping open as air moves through.
Doctors also check the fingers. A condition called digital clubbing, where the fingertips become wider and rounder, shows up in some patients with fibrotic lung disease. The reported prevalence ranges widely, from 7% to 52% depending on the type of fibrosis and how clubbing is measured. Clubbing isn’t unique to pulmonary fibrosis, but combined with crackles and shortness of breath, it raises suspicion quickly.
High-Resolution CT Scan
A high-resolution CT scan (HRCT) of the chest is the single most important diagnostic tool. Standard chest X-rays can miss early fibrosis or show only vague haziness. HRCT produces detailed cross-sectional images that reveal the specific pattern and distribution of scarring in the lungs.
Doctors look for a pattern called usual interstitial pneumonia, or UIP, which is the hallmark of idiopathic pulmonary fibrosis (the most common type). Key features include a honeycomb-like appearance, where clusters of small cysts form in damaged areas, along with irregular thickening of the tissue between air sacs. The scarring in UIP tends to concentrate in the lower portions of the lungs and along the outer edges, closer to the rib cage. When the CT clearly shows this pattern, a tissue biopsy may not be needed at all.
Not every scan is clear-cut, though. International guidelines from the American Thoracic Society and partner organizations classify CT findings into categories: definite UIP, probable UIP, indeterminate, or an alternative diagnosis. When the pattern is only “probable” or “indeterminate,” further testing is usually required to reach a confident diagnosis.
Pulmonary Function Tests
Breathing tests, formally called pulmonary function tests, measure how well your lungs move air and transfer oxygen into your blood. Two values matter most in pulmonary fibrosis.
The first is forced vital capacity (FVC), which measures the total amount of air you can forcefully exhale after a deep breath. In pulmonary fibrosis, FVC drops because scarred lungs can’t expand fully. A result below roughly 80% of the predicted value for your age, sex, and height suggests a restrictive pattern, meaning the lungs are stiffer or smaller than they should be. Moderate restriction falls between 40% and 60% of predicted, and anything below 40% is considered severe.
The second key measurement is diffusing capacity (DLCO), which tests how efficiently oxygen passes from your lungs into your bloodstream. Fibrosis thickens the tissue between air sacs and blood vessels, creating a barrier that slows gas exchange. A low DLCO can appear even before other tests show obvious abnormalities, making it one of the earliest measurable signs. These tests are also repeated over time to track how quickly the disease is progressing, which directly influences treatment decisions.
Blood Tests to Rule Out Other Causes
Lung scarring isn’t always idiopathic (meaning “no known cause”). Autoimmune diseases like rheumatoid arthritis, scleroderma, and inflammatory muscle diseases can all cause fibrosis that looks similar on imaging. Blood tests help sort this out.
A standard workup includes a panel of autoantibodies: markers associated with rheumatoid arthritis (like rheumatoid factor and anti-CCP antibodies), scleroderma-related antibodies, antinuclear antibodies, and a range of antibodies linked to inflammatory muscle disease. If any of these come back positive, the lung scarring may be part of a broader autoimmune condition rather than idiopathic pulmonary fibrosis. This distinction matters because the treatment approach differs significantly. Autoimmune-related fibrosis often responds to medications that suppress the immune system, while idiopathic pulmonary fibrosis does not.
When a Tissue Sample Is Needed
If the CT scan doesn’t show a clear-cut pattern, doctors may need a tissue sample to examine the lung scarring under a microscope. There are a few ways to get one, each with different tradeoffs.
Bronchoalveolar lavage (BAL) involves threading a thin, flexible scope through the airways and washing a small section of lung with saline, then collecting the fluid for analysis. It’s relatively low-risk, with a complication rate around 8%, and is especially useful for ruling out infections or certain inflammatory conditions. However, it rarely provides enough information on its own to confirm a fibrotic diagnosis.
Transbronchial cryobiopsy is a newer, less invasive option. A probe is passed through the airways and uses extreme cold to freeze and extract a small piece of lung tissue. The samples are larger than those from traditional transbronchial biopsy, giving pathologists more to work with. This approach has gained traction as a middle ground between the limited yield of BAL and the higher risks of surgery.
Surgical lung biopsy, performed either through small incisions (video-assisted thoracoscopic surgery) or a larger opening, provides the largest and most reliable tissue samples. It is more likely to yield a definitive non-infectious diagnosis and to change patient management compared to less invasive approaches. But it carries a complication rate roughly double that of BAL and a procedure-related mortality rate about four times higher, so it’s generally reserved for cases where the diagnosis genuinely can’t be made any other way.
Genomic Testing as a Newer Option
A relatively recent addition to the diagnostic toolkit is a genomic test that can be run on tissue obtained through a standard bronchoscopy. The Envisia Genomic Classifier analyzes gene expression patterns in a small transbronchial biopsy sample to predict whether the underlying pattern is UIP. It has a specificity of 92%, meaning it’s very reliable when it says the pattern is UIP, though its sensitivity is 68%, so it misses some true cases. For patients whose CT scans are inconclusive and who want to avoid surgical biopsy, this test can sometimes provide enough confidence to make a diagnosis without an operation.
Why It Often Takes So Long
The early symptoms of pulmonary fibrosis, mainly a dry cough and gradually worsening shortness of breath during exertion, overlap with many common conditions. In the IPF-PRO Registry, nearly half of patients had received antibiotics for presumed pneumonia in the two years before their actual diagnosis. Others were initially treated for COPD or heart failure. Because the disease tends to affect people over 50, it’s easy to attribute mild breathlessness to aging or deconditioning.
The diagnosis typically solidifies only after a patient is referred to a pulmonologist, and ideally to a multidisciplinary team that includes a pulmonologist, radiologist, and pathologist reviewing the case together. This team-based approach, where each specialist interprets their piece of the puzzle alongside the others, is considered the gold standard for reaching an accurate diagnosis and has been endorsed by every major international guideline on the disease.